The US-based clinical-stage medical device company, Coologics, announced the successful closure of an oversubscribed seed funding round for its innovative vaginal infection treatment device, Vlisse, raising more than $3 million.
Prevail and Dream Ventures led the funding round along with participation from university alumni groups including Ohio State Early Investor Network and Illinois Ventures Illini Angels Program.
Coologics, founded by Dr. Langdon with Dr. Nicole Williams, serving as Chief Medical Officer, aims to transform women’s health with its approach of restoring the vaginal environment to a healthy state without chemicals. The successful funding round is a big milestone for the company planning to introduce this technology to market.
“We are beyond excited about the investor commitment to Coologics,” said Dr. Kim Langdon, Coologics CEO & Founder. “The overwhelming interest in our seed round validates the critical need for a more effective treatment for vaginal infections. We are thrilled to welcome our new investors and leverage their expertise to accelerate our growth and deliver impactful solutions to female patients and their clinicians.”
“Dr. Langdon’s vision and passion for this problem is what excited us the most about Coologics,” said Kerry Lawing, Prevail Ventures CEO. “This market is ripe for innovative solutions like Vlisse. I look forward to watching our experienced teams at Prevail and Dream strategically support Coologics efforts in bringing Vlisse to market.”
The funding will be used for the completion of Coologics’ ongoing clinical trial, FDA submission, and initial market release of Vlisse. The company’s focus on drug-free solutions are aimed to reduce the growing concerns about antibiotic resistance while providing alternatives for women to manage common vaginal infections.
